With TRAIL-based therapies already being explored in many other cancer types, our findings further justify the investigation of these therapies specifically tailored for CRC.[49,55,56] We recognize that while our findings are promising, further preclinical and clinical studies are still needed. Here, TNFSF10 is linked to colorectal carcinoma.